mediates for which enough capacities have been created and lying idle as well as self sufficiency attained which are allowed under OGL;

(f) if so, whether his Ministry has made any study in this direction; and

(g) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a)to (d) Import Policy is determined by the Ministry of Commerce after taking into consideration various recommendations and factors. The same principle applies to drugs also.

(e) to (g) As and when requests for making changes in the import policy are received from the industry, the same are examined and recommendations made to the C.C.I. & E. accordingly.

Payment made for buying off-shore Platforms

715. SHRI RAOOF VALIULLAH:
SHRI HARVENDRA SINGH HANSPAL:
SHRI ASHOK NATH VERMA:
KUMARI SUSHILA TIRIA:

Will the Minister of PETROLEUM AND NATURAL GAS be pleased to state:

(a) whether it is a fact that avoidable payment of Rs. 5 crore was made to a contractor by ONGC while buying off-shore KVX platforms;

(b) if so, whether responsibility has been fixed on the concrned persons for unauthorised deviation of the agreed conditions of the contract and action taken against them; and

(c) whether the Comptroller and Auditor General of India has indicted the ONGC for this lapse?

THE DEPUTY MINISTER IN THE MINISTRY OF PETROLEUM AND NATURAL GAS (SHRI RAFIQUE ALAM): (a) to (c) On a review of the ONGC contract for purchase of SK, NV and NX platforms, also known as KVX platforms, the Audit had pointed out that there has been an unauthorised deviation from the general conditions of the contract which resulted in an undue benefit of Rs. 5.10 crores to the contractor. This matter has been referred to the Central Bureau of Investigation.

Production stage of Rifampicin

716. SHRI JASWANT SINGH:
SHRI DAYANAND SAHAY:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3386 given in the Rajya Sabha on the 24th August, 1987 and state:

(a) what is the stage from which each producer of Rifampicin was allowed to be produced along with the capacity sanctioned in each case;

(b) since when each producer is producing Rifampicin along with the stage of manufacture;

(c) whether his Ministry is monitoring the production of Rifampicin,

(d) if so, what was the production of each producer during the last three years, year-wise;

(e) whether it is a fact that BICP conducted cost-cum-technical study of production of Rifampicin;

(f) what was the price at which intermediate or penaltimate was found to be imported;

(g) what price was recommended for Rifampicin by BICP;

(h) whether any unit is producing from basic stage; and